恶性梗阻性黄疸PTCD治疗体会  

Percutaneous Transhepatic Biliary Drainage in Patients with Malignant Obstructive Jaundice

作　　者：王乃宏[1] 张继青[1] 王佳[1] 

机构地区：[1]山东新汶矿业集团中心医院介入科,山东271233

出　　处：《当代医学》2012年第6期73-75,共3页Contemporary Medicine

摘　　要：目的探讨PTCD对恶性梗阻性黄疸的治疗价值。方法 76例恶性梗阻性黄疸患者,57例行胆道支架植入治疗,19例行外引流或内外引流管留置。比较治疗前后谷丙转氨酶、谷草转氨酶及血清胆红素变化,支架组和引流管组生存时间差别。结果治疗后谷丙转氨酶、谷草转氨酶及血清胆红素均明显下降。支架组平均生存期为14.2个月,引流管组平均生存期8.6个月。结论引流通畅的胆道支架植入治疗安全、有效,较单纯引流管留置术可以明显延长病人的生存期。Objective To discuss the therapeutic value of percutaneous transhepatic biliary drainage （PTCD） in the treatment of malignant obstructive jaudice. Methods Seventy-six patients with malignant obstructive jaundice were admitted. Fifty-seven of them were treated with biliary stenting, while nineteen with ext＇etnal drainage or external and internal drainage. Pre- and post-procedural ALT, AST and bilirubin were compared between stenting and drainage groups. Results Post-procedural ALT, AST and bilirubin decreased significantly than that of preprocedure. Average survival time of stenfing and drainage groups was 14.2 and 8,6 months respectively. Conclusion Biliary stenting with good patency is safe and effective. Compared with drainage, stenting can significantly prolong survival time of patients.

关 键 词：恶性梗阻性黄疸 介入治疗 支架植入 引流 生存期 

分 类 号：R735[医药卫生—肿瘤]